ClinicalTrials.gg
Not yet recruitingNCT07856875Updated Oct 5, 2026

Platelet-Rich Fibrin for Preventing Osteoradionecrosis After Dental Extractions

An interventional study of Platelet-rich fibrin (PRF) and Standard Dental Extraction Care in Osteoradionecrosis of the Jaw, sponsored by University of Manitoba. Not yet recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by University of Manitoba · Not applicable, Interventional, and Prevention

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn whether platelet-rich fibrin (PRF) can help prevent osteoradionecrosis (ORN) after dental extractions in adults who previously received radiation therapy to the head and neck. ORN is a condition in which jawbone damaged by radiation does not heal properly and may become exposed.

The main question this study aims to answer is:

Does placing PRF into dental extraction sites lower the chance of developing ORN within 6 months after extraction?

PRF is made from a small sample of a participant's own blood. The blood is processed in a centrifuge to form PRF, which can then be placed into the tooth extraction site.

Researchers will compare participants who receive PRF in addition to standard extraction care with participants who receive standard extraction care alone.

Participants will:

Have one or more teeth removed from an area of the jaw that previously received radiation therapy.

Be randomly assigned to receive either PRF plus standard care or standard care alone.

Return for follow-up visits at approximately 2 weeks, 6 weeks, 3 months, and 6 months after extraction.

Have their healing, pain, any potential postoperative complications, and development of ORN assessed during follow-up.

Read the detailed description

This is a multicentre, randomized controlled trial evaluating platelet-rich fibrin (PRF) for the prevention of osteoradionecrosis (ORN) following dental extraction in adults who have previously received radiation therapy involving the jaws.

Eligible participants requiring extraction of one or more teeth within a previously irradiated field will be randomized in a 1:1 ratio to receive either PRF plus standard extraction care or standard extraction care alone.

For participants allocated to the intervention group, autologous PRF will be prepared chairside from venous blood using horizontal centrifugation and placed into the extraction socket(s) during the same procedure. The PRF will not be stored or transported.

The study will evaluate whether adjunctive PRF reduces the occurrence of ORN following dental extraction and will also evaluate clinical soft-tissue healing, radiographic bone healing, postoperative pain, analgesic use, postoperative complications, and adverse events.

The study will be conducted at participating centres in Winnipeg, Manitoba, and Calgary, Alberta, Canada.

02

Conditions studied

  • Osteoradionecrosis of the Jaw

Browse trials for

Keywords

  • Osteoradionecrosis
  • ORN
  • Platelet-Rich Fibrin
  • PRF
  • Dental Extraction
  • Radiation Therapy
  • Head and Neck Radiation
  • Jaw
  • Post-Radiation Dental Extraction
03

In context

Osteoradionecrosis

24 studies on the registry are indexed under Osteoradionecrosis; 8 are open to participants now.

This study's planned enrollment of 112 is above the median of 60 across 13 interventional studies indexed under Osteoradionecrosis.

Browse Osteoradionecrosis studies →

Lead sponsor

University of Manitoba is the lead sponsor of 555 studies on the registry; 88 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 5 (42%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age 18 years or older. History of head and neck cancer treated with radiation therapy. Requires at least one dental extraction within an area of the jaw that was previously treated with radiation.

Willing and able to attend all study follow-up visits. No minimum or maximum time since completion of radiation therapy is required.

Exclusion criteria

Exclusion Criteria:

Abscess or draining sinus tract associated with a planned study extraction site.

Blood disorder affecting production or function, such as thrombocytopenia, hemophilia, von Willebrand disease, or a qualitative platelet disorder.

Current therapy, including calcineurin inhibitors, antimetabolites, biologic therapy, or active cytotoxic chemotherapy.

Current tobacco use in any form, including nicotine vaping, within the previous 30 days.

Known recurrence of head and neck cancer. Previous re-irradiation or re-irradiation currently planned. Chronic systemic use equivalent to at least 5 mg of prednisone daily for at least 30 consecutive days within the previous 3 months.

Current or previous bisphosphonate therapy by any route. Denosumab within the previous 12 months or use of another antiresorptive or antiangiogenic medication.

Current pregnancy. Therapeutic low-molecular-weight heparin or unfractionated heparin that cannot be scheduled at trough level.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    Platelet-Rich Fibrin (PRF) + Standard Care

    Participants randomized to this arm will undergo dental extraction with standard extraction care and adjunctive placement of autologous platelet-rich fibrin (PRF) into the extraction socket(s). PRF will be prepared chairside from the participant's venous blood using horizontal centrifugation and placed into the extraction socket(s) during the same procedure.

    Procedure: Platelet-rich fibrin (PRF) · Procedure: Standard Dental Extraction Care

  • Active comparator
    Standard Care Alone

    Participants randomized to this arm will undergo dental extraction with standard extraction care without placement of platelet-rich fibrin (PRF) into the extraction socket(s).

    Procedure: Standard Dental Extraction Care

Interventions

  • ProcedurePlatelet-rich fibrin (PRF)

    Autologous platelet-rich fibrin (PRF) will be prepared chairside from venous blood collected from the participant. Blood will be processed using horizontal centrifugation to produce PRF. The prepared PRF will be placed into the eligible dental extraction socket(s) during the same procedure. PRF will not be stored or transported.

  • ProcedureStandard Dental Extraction Care

    Participants will undergo extraction of one or more eligible teeth within a previously irradiated area of the jaw using standard dental extraction care. No platelet-rich fibrin (PRF) will be placed in the extraction socket(s) as part of this intervention.

06

What researchers measure

Primary outcomes

  1. Incidence of Osteoradionecrosis Within 6 Months

    Osteoradionecrosis (ORN) will be assessed at the participant level using the ClinRad definition adopted by the ISOO-MASCC-ASCO guideline. ORN is defined as a radiographic lytic or mixed sclerotic lesion of bone, visibly exposed bone, and/or bone probeable through a periodontal pocket or fistula within an anatomical site previously exposed to therapeutic head and neck radiation. A participant will meet the primary endpoint if at least one study extraction socket meets the definition at any scheduled or unscheduled visit through 6 months.

    Time frame: From dental extraction through 6 months after extraction

Secondary outcomes

  1. Complete Mucosal Closure of the Extraction Site

    Complete mucosal closure will be assessed clinically at each study extraction socket and recorded as a binary outcome (yes/no). Complete mucosal closure is defined as intact epithelium across the entire socket orifice, with no dehiscence and no exposed bone. Socket-level outcomes will account for clustering of multiple extraction sockets within individual participants.

    Time frame: 2 weeks, 6 weeks, 3 months, and 6 months after dental extraction

  2. Radiographic Bone Healing at the Extraction Site

    Radiographic bone healing at each study extraction site will be assessed by qualitative comparison of the 6-month cone-beam computed tomography (CBCT) scan with the pre-extraction baseline CBCT. Assessment will include the presence, absence, and extent of lytic or mixed sclerotic changes and cortical continuity at the socket crest.

    Time frame: Baseline to 6 months after dental extraction

  3. Postoperative Pain Intensity

    Pain intensity at each study extraction socket will be assessed using the 11-point Numeric Rating Scale (NRS-11), ranging from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable. Participants will rate pain at each extraction site over the preceding 24 hours. Higher scores indicate greater pain intensity.

    Time frame: 2 weeks, 6 weeks, 3 months, and 6 months after dental extraction

07

Study locations

2 sites
  • Arthur J.E. Child Comprehensive Cancer Centre Dental Clinic
    Calgary, Alberta T2N 5G2, Canada
  • Health Sciences Centre Oral Surgery Clinic
    Vancouver, British Columbia V6T 1X4, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 5, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856875
Responsible party
Reda Elgazzar (Associate Professor, University of Manitoba) — Principal investigator
First posted
Oct 5, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Julia M Burgess, DMD (current OMFS Resident)
Contact
burges16@myumanitoba.ca
6042206648
Reda Elgazzar, Oral and Maxillofacial Surgeon
Contact
Reda.Elgazzar@umanitoba.ca
2047893634
Julia M Burgess, DMD (current OMFS Resident)
principal investigator · University of Manitoba
Reda Elgazzar, Oral and Maxillofacial Surgeon
study director · University of Manitoba
Edmund Chan, DMD
study director · University of Calgary

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion